174 related articles for article (PubMed ID: 38594603)
1. Habitat escalated adaptive therapy (HEAT): a phase 2 trial utilizing radiomic habitat-directed and genomic-adjusted radiation dose (GARD) optimization for high-grade soft tissue sarcoma.
Naghavi AO; Bryant JM; Kim Y; Weygand J; Redler G; Sim AJ; Miller J; Coucoules K; Michael LT; Gloria WE; Yang G; Rosenberg SA; Ahmed K; Bui MM; Henderson-Jackson EB; Lee A; Lee CD; Gonzalez RJ; Feygelman V; Eschrich SA; Scott JG; Torres-Roca J; Latifi K; Parikh N; Costello J
BMC Cancer; 2024 Apr; 24(1):437. PubMed ID: 38594603
[TBL] [Abstract][Full Text] [Related]
2. MRI-based delta-radiomics predicts pathologic complete response in high-grade soft-tissue sarcoma patients treated with neoadjuvant therapy.
Peeken JC; Asadpour R; Specht K; Chen EY; Klymenko O; Akinkuoroye V; Hippe DS; Spraker MB; Schaub SK; Dapper H; Knebel C; Mayr NA; Gersing AS; Woodruff HC; Lambin P; Nyflot MJ; Combs SE
Radiother Oncol; 2021 Nov; 164():73-82. PubMed ID: 34506832
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Magnetic resonance imaging (MRI)-based radiomics for prostate cancer radiotherapy.
Yang F; Ford JC; Dogan N; Padgett KR; Breto AL; Abramowitz MC; Dal Pra A; Pollack A; Stoyanova R
Transl Androl Urol; 2018 Jun; 7(3):445-458. PubMed ID: 30050803
[TBL] [Abstract][Full Text] [Related]
5. Natural Changes in Radiological and Radiomics Features on MRIs of Soft-Tissue Sarcomas Naïve of Treatment: Correlations With Histology and Patients' Outcomes.
Fadli D; Kind M; Michot A; Le Loarer F; Crombé A
J Magn Reson Imaging; 2022 Jul; 56(1):77-96. PubMed ID: 34939705
[TBL] [Abstract][Full Text] [Related]
6. CT-based radiomic features predict tumor grading and have prognostic value in patients with soft tissue sarcomas treated with neoadjuvant radiation therapy.
Peeken JC; Bernhofer M; Spraker MB; Pfeiffer D; Devecka M; Thamer A; Shouman MA; Ott A; Nüsslin F; Mayr NA; Rost B; Nyflot MJ; Combs SE
Radiother Oncol; 2019 Jun; 135():187-196. PubMed ID: 30961895
[TBL] [Abstract][Full Text] [Related]
7. Multiparametric magnetic resonance imaging for radiation therapy response monitoring in soft tissue sarcomas: a histology and MRI co-registration algorithm.
Jung M; Bogner B; Diallo TD; Kim S; Arnold P; Füllgraf H; Kurowski K; Bronsert P; Jungmann PM; Kiefer J; Kraus D; Rovedo P; Reisert M; Eisenhardt SU; Bamberg F; Benndorf M; Runkel A
Theranostics; 2023; 13(5):1594-1606. PubMed ID: 37056570
[No Abstract] [Full Text] [Related]
8. Prostate cancer radiomics and the promise of radiogenomics.
Stoyanova R; Takhar M; Tschudi Y; Ford JC; Solórzano G; Erho N; Balagurunathan Y; Punnen S; Davicioni E; Gillies RJ; Pollack A
Transl Cancer Res; 2016 Aug; 5(4):432-447. PubMed ID: 29188191
[TBL] [Abstract][Full Text] [Related]
9. Genomic identification of sarcoma radiosensitivity and the clinical implications for radiation dose personalization.
Yang G; Yuan Z; Ahmed K; Welsh EA; Fulp WJ; Gonzalez RJ; Mullinax JE; Letson D; Bui M; Harrison LB; Scott JG; Torres-Roca JF; Naghavi AO
Transl Oncol; 2021 Oct; 14(10):101165. PubMed ID: 34246048
[TBL] [Abstract][Full Text] [Related]
10. Non-invasive monitoring of neoadjuvant radiation therapy response in soft tissue sarcomas by multiparametric MRI and quantification of circulating tumor DNA-A study protocol.
Runkel A; Braig D; Bogner B; Schmid A; Lausch U; Boneberg A; Brugger Z; Eisenhardt A; Kiefer J; Pauli T; Boerries M; Fuellgraf H; Kurowski K; Bronsert P; Scholber J; Grosu AL; Rovedo P; Bamberg F; Eisenhardt SU; Jung M
PLoS One; 2023; 18(11):e0285580. PubMed ID: 37910565
[TBL] [Abstract][Full Text] [Related]
11. A clinicogenomic model including GARD predicts outcome for radiation treated patients with HPV+ oropharyngeal squamous cell carcinoma.
Ho E; De Cecco L; Cavalieri S; Sedor G; Hoebers F; Brakenhoff RH; Scheckenbach K; Poli T; Yang K; Scarborough JA; Campbell S; Koyfman S; Eschrich SA; Caudell JJ; Kattan MW; Licitra L; Torres-Roca JF; Scott JG
medRxiv; 2023 Sep; ():. PubMed ID: 37745365
[TBL] [Abstract][Full Text] [Related]
12. Soft tissue sarcoma and radiation therapy advances, impact on toxicity.
El-Bared N; Wong P; Wang D
Curr Treat Options Oncol; 2015 May; 16(5):19. PubMed ID: 25859829
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of neoadjuvant conformal radiotherapy plus sorafenib for patients with locally advanced soft tissue sarcoma of the extremity.
Canter RJ; Borys D; Olusanya A; Li CS; Lee LY; Boutin RD; Christensen SD; Tamurian RM; Monjazeb AM
Ann Surg Oncol; 2014 May; 21(5):1616-23. PubMed ID: 24554062
[TBL] [Abstract][Full Text] [Related]
14. Radiomic Features From Diffusion-Weighted MRI of Retroperitoneal Soft-Tissue Sarcomas Are Repeatable and Exhibit Change After Radiotherapy.
Thrussell I; Winfield JM; Orton MR; Miah AB; Zaidi SH; Arthur A; Thway K; Strauss DC; Collins DJ; Koh DM; Oelfke U; Huang PH; O'Connor JPB; Messiou C; Blackledge MD
Front Oncol; 2022; 12():899180. PubMed ID: 35924167
[TBL] [Abstract][Full Text] [Related]
15. Preoperative hypofractionated radiotherapy for soft tissue sarcomas: a systematic review.
Roohani S; Ehret F; Kobus M; Flörcken A; Märdian S; Striefler JK; Rau D; Öllinger R; Jarosch A; Budach V; Kaul D
Radiat Oncol; 2022 Sep; 17(1):159. PubMed ID: 36104789
[TBL] [Abstract][Full Text] [Related]
16. Moderate hypofractionated radiation therapy and pathologic response for soft tissue sarcomas (STS) of limbs and trunk: experience from a tertiary cancer center.
Montero A; Chen-Zhao X; Ciérvide R; Álvarez B; Prado A; López M; Sánchez E; Hernando O; de la Casa MA; García-Aranda M; Valero J; Alonso R; Fernández-Letón P; Rubio C
Clin Transl Oncol; 2024 Jan; 26(1):204-213. PubMed ID: 37277526
[TBL] [Abstract][Full Text] [Related]
17. Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial.
Guadagnolo BA; Bassett RL; Mitra D; Farooqi A; Hempel C; Dorber C; Willis T; Wang WL; Ratan R; Somaiah N; Benjamin RS; Torres KE; Hunt KK; Scally CP; Keung EZ; Satcher RL; Bird JE; Lin PP; Moon BS; Lewis VO; Roland CL; Bishop AJ
Lancet Oncol; 2022 Dec; 23(12):1547-1557. PubMed ID: 36343656
[TBL] [Abstract][Full Text] [Related]
18. Clinical phase I/II trial to investigate preoperative dose-escalated intensity-modulated radiation therapy (IMRT) and intraoperative radiation therapy (IORT) in patients with retroperitoneal soft tissue sarcoma: interim analysis.
Roeder F; Ulrich A; Habl G; Uhl M; Saleh-Ebrahimi L; Huber PE; Schulz-Ertner D; Nikoghosyan AV; Alldinger I; Krempien R; Mechtersheimer G; Hensley FW; Debus J; Bischof M
BMC Cancer; 2014 Aug; 14():617. PubMed ID: 25163595
[TBL] [Abstract][Full Text] [Related]
19. Significant Reduction of Late Toxicities in Patients With Extremity Sarcoma Treated With Image-Guided Radiation Therapy to a Reduced Target Volume: Results of Radiation Therapy Oncology Group RTOG-0630 Trial.
Wang D; Zhang Q; Eisenberg BL; Kane JM; Li XA; Lucas D; Petersen IA; DeLaney TF; Freeman CR; Finkelstein SE; Hitchcock YJ; Bedi M; Singh AK; Dundas G; Kirsch DG
J Clin Oncol; 2015 Jul; 33(20):2231-8. PubMed ID: 25667281
[TBL] [Abstract][Full Text] [Related]
20. A clinical phase I/II trial to investigate preoperative dose-escalated intensity-modulated radiation therapy (IMRT) and intraoperative radiation therapy (IORT) in patients with retroperitoneal soft tissue sarcoma.
Roeder F; Schulz-Ertner D; Nikoghosyan AV; Huber PE; Edler L; Habl G; Krempien R; Oertel S; Saleh-Ebrahimi L; Hensley FW; Buechler MW; Debus J; Koch M; Weitz J; Bischof M
BMC Cancer; 2012 Jul; 12():287. PubMed ID: 22788989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
